Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

RESMED INC.

(RMD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

ResMed Inc. : A good level to buy

10/19/2021 | 02:52am EST
long trade
Live
Entry price : 261.08$ | Target : 297$ | Stop-loss : 240$ | Potential : 13.76%
The recent downward movement has sent ResMed Inc. shares back to attractive levels situated around 237.44 USD. This zone could put an end to the downward movement and offers a good timing for new long positions.
Investors have an opportunity to buy the stock and target the $ 297.
ResMed Inc. : ResMed Inc. : A good level to buy
Summary
  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 43.63 times its estimated earnings per share for the ongoing year.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is highly valued given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.
Ratings chart
Subsector Other Advanced Medical Equipment & Technology
1st jan.Capitalization (M$)Investor Rating
RESMED INC.19.86%26 725
THERMO FISHER SCIENTIFIC36.57%250 658
DANAHER CORPORATION40.88%223 620
INTUITIVE SURGICAL, INC.20.03%114 898
SIEMENS HEALTHINEERS AG52.50%80 761
EDWARDS LIFESCIENCES CORPOR..20.38%67 728
SHENZHEN MINDRAY BIO-MEDICA..-17.14%67 133
BOSTON SCIENTIFIC CORPORATI..6.09%56 230
ILLUMINA, INC.-3.34%54 280
AGILENT TECHNOLOGIES, INC.25.08%45 206
PHILIPS NV-29.00%30 591
More Results

ę MarketScreener.com 2021

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2022 3 826 M - -
Net income 2022 876 M - -
Net Debt 2022 116 M - -
P/E ratio 2022 43,4x
Yield 2022 0,67%
Capitalization 26 725 M 26 725 M -
EV / Sales 2022 7,01x
EV / Sales 2023 6,47x
Nbr of Employees 7 970
Free-Float 77,1%
Upcoming event on RESMED INC.
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Last Close Price 254,78 $
Average target price 263,13 $
Spread / Average Target 3,28%
EPS Revisions
Managers and Directors
Michael J. Farrell Chief Executive Officer & Director
Robert Andrew Douglas President & Chief Operating Officer
Brett A. Sandercock Chief Financial Officer
Peter C. Farrell Non-Executive Chairman
Carlos M. Nunez Chief Medical Officer